-+ 0.00%
-+ 0.00%
-+ 0.00%
According to Shanwaishan's announcement, Chongqing Tianwaitian Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, recently received the “People's Republic of China Medical Device Registration Certificate” issued by the State Drug Administration. The product is a single-use hemodialysis pipeline. The registration category is first-time registration, and the management category is Class III, which is valid until July 19, 2031. The acquisition of this product registration certificate is a milestone in the company's commercialization of R&D results. It will improve the company's product matrix and enhance competitiveness, but the actual sales situation of the product cannot be predicted.
Share
Listen to the news
According to Shanwaishan's announcement, Chongqing Tianwaitian Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, recently received the “People's Republic of China Medical Device Registration Certificate” issued by the State Drug Administration. The product is a single-use hemodialysis pipeline. The registration category is first-time registration, and the management category is Class III, which is valid until July 19, 2031. Obtaining this product registration certificate is a milestone in the company's commercialization of R&D results. It will improve the company's product matrix and enhance competitiveness, but the actual sales situation of the product cannot be predicted.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending